- Research article
- Open Access
Epigenetic silencing and deletion of the BRCA1gene in sporadic breast cancer
Breast Cancer Research volume 8, Article number: R38 (2006)
BRCA1 or BRCA2 germline mutations increase the risk of developing breast cancer. Tumour cells from germline mutation carriers have frequently lost the wild-type allele. This is predicted to result in genomic instability where cell survival depends upon dysfunctional checkpoint mechanisms. Tumorigenic potential could then be acquired through further genomic alterations. Surprisingly, somatic BRCA mutations are not found in sporadic breast tumours. BRCA1 methylation has been shown to occur in sporadic breast tumours and to be associated with reduced gene expression. We examined the frequency of BRCA1 methylation in 143 primary sporadic breast tumours along with BRCA1 copy number alterations and tumour phenotype.
Primary sporadic breast tumours were analysed for BRCA1α promoter methylation by methylation specific PCR and for allelic imbalance (AI) at BRCA1 and BRCA2 loci by microsatellite analysis and TP53 (also known as p53) mutations by constant denaturing gel electrophoresis. The BRCA1 methylated tumours were analysed for BRCA1 copy alterations by fluorescence in situ hybridisation and BRCA1 expression by immunostaining.
BRCA1 methylation was found in 13/143 (9.1%) sporadic breast tumours. The BRCA1 methylated tumours were significantly associated with estrogen receptor (ER) negativity (P = 0.0475) and displayed a trend for BRCA1 AI (P = 0.0731) as well as young-age at diagnosis (≤ 55; P = 0.0898). BRCA1 methylation was not associated with BRCA2 AI (P = 0.5420), although a significant association was found between BRCA1 AI and BRCA2 AI (P < 0.0001).
Absent/markedly reduced BRCA1 expression was observed in 9/13 BRCA1 methylated tumours, most of which had BRCA1 deletion. An elevated TP53 mutation frequency was found among BRCA1 methylated tumours (38.5%) compared with non-methylated tumours (17.2%). The BRCA1 methylated tumours were mainly of tumour grade 3 (7/13) and infiltrating ductal type (12/13). Only one methylated tumour was of grade 1.
BRCA1 methylation is frequent in primary sporadic breast tumours. We found an indication for BRCA1 methylation to be associated with AI at the BRCA1 locus. Almost all BRCA1 methylated tumours with absent/markedly reduced BRCA1 expression (8/9) displayed BRCA1 deletion. Thus, epigenetic silencing and deletion of the BRCA1 gene might serve as Knudson's two 'hits' in sporadic breast tumorigenesis. We observed phenotypic similarities between BRCA1 methylated and familial BRCA1 tumours, based on BRCA1 deletion, TP53 mutations, ER status, young age at diagnosis and tumour grade.
Germline mutations in one allele of the BRCA1 or BRCA2 genes significantly increase the risk of developing early-onset breast cancer . Tumour cells from predisposed individuals have consistently lost the wild-type BRCA allele [2, 3]. The most prominent feature of BRCA deficient cells is the inability to repair DNA cross-links and DNA double-strand breaks by error-free homologous recombination, which probably underlies genomic instability and cancer predisposition . Survival of BRCA deficient cells is generally thought to be dependent upon dysfunctional checkpoint mechanisms, in which case tumorigenic potential could be acquired through additional genomic rearrangements and gene mutations. Indeed, familial BRCA1 tumours are associated with mutations in the TP53 checkpoint gene, supporting the notion that genomic instability is an important driving force in early-onset familial BRCA1 tumorigenesis .
Although inherited cancer syndromes are rare, the genes accounting for them are generally believed to play an important role in sporadic cancer. It was anticipated, therefore, that somatic BRCA mutations would be found to contribute to sporadic breast carcinogenesis. Surprisingly, somatic BRCA gene mutations have not been found in sporadic breast tumours [6, 7]. On the other hand, allelic imbalance (AI) at the BRCA loci, an indicator for loss of heterozygosity, is know to be a fairly common event in breast cancer . The implications of AI at the BRCA loci are unknown since Knudson's hypothesis predicts an additional inactivating event on top of AI to be required for tumorigenesis to occur . For these reasons, the involvement of the BRCA genes in sporadic breast tumours has been questioned. An alternative mechanism for BRCA1 inactivation has been suggested to be gene silencing by epigenetic mechanisms. Hypermethylation of CpG-island promoters is known to be strongly associated with gene silencing. Once established, methylation is passed on to daughter cells during DNA replication by the activity of DNA methyltransferases, thereby conserving the overall pattern of methylated CpG-islands . The methylation patterns of virtually all types of cancer, including breast carcinoma, have been found to differ extensively from that of the corresponding normal tissue. These alterations are cancer-type specific and include global genomic hypomethylation as well as non-random hypermethylation of normally unmethylated CpG-island promoters [11, 12]. These observations, and others, indicate that epigenetic modifications could be important in cancer etiology .
Several studies have reported hypermethylation of the BRCA1 promoter in sporadic breast and ovarian tumours. Furthermore, BRCA1 methylation has only been found in breast and ovarian tumours and has been associated with AI at the BRCA1 locus and reduced BRCA1 gene expression [12, 14]. BRCA2 promoter hypermethylation has not been found in breast tumours, although it has been reported in ovarian tumours [15, 16].
Familial BRCA1 and BRCA2 tumours are associated with young age of onset and are phenotypically distinct from each other as well as from sporadic breast tumours [1, 17–19]. Conventional histopathological and molecular analyses have demonstrated familial BRCA1 tumours to have a basal-like phenotype and to be significantly associated with certain features, such as AI at the BRCA1 locus, a negative estrogen receptor (ER) and progesterone receptor (PR) status, a medullary tumour histological type, TP53 mutations and, depending on the mutation involved, a high tumour grade [3, 5, 18, 20, 21]. Interestingly, gene expression profiling has revealed similarities between BRCA1 methylated and familial BRCA1 tumours [17, 22]. Similarly, a comparative genomic hybridisation study has reported a specific pattern of genetic alterations to be predictive of familial BRCA1 tumours and BRCA1 methylated tumours . This lends support to the idea that epigenetic silencing of the BRCA1 gene might channel tumour progression, akin to an underlying BRCA1 germline mutation resulting in a BRCA-like phenotype. However, a recent report showing high levels of BRCA1 expression and a low frequency of BRCA1 promoter methylation in basal-like sporadic tumours suggests that this might be more complex .
In the present study, we examined the frequency of BRCA1α promoter hypermethylation in 143 unselected primary sporadic breast tumours. All tumours were analysed for AI at the BRCA1 and BRCA2 loci, TP53 mutations, hormonal receptor status and age at diagnosis. Copy number alterations at the BRCA1 locus were further examined by fluorescence in situ hybridisation (FISH) in the BRCA1 methylated tumours which were also analysed for BRCA1 protein expression, histological type and tumour grade. The purpose of the study was to examine whether the BRCA1 gene could be implicated in sporadic breast tumorigenesis through epigenetic modifications.
Materials and methods
The study group consisted of 143 female breast cancer patients that carried neither the Icelandic BRCA1 5193G→A nor the BRCA2 999del5 germline mutations [25, 26]. DNA samples from these patients were obtained from the Biological Specimen Bank of the Icelandic Cancer Society. Tumour DNA (obtained from fresh/frozen primary breast cancer tissue) and normal DNA (obtained from blood or from fresh/frozen breast tissue adjacent to the breast cancer tissue) were available from each of the patients. Data on tumour grade (Nottingham tumour grade), histological type, ER and PR status, flow-cytometric DNA index and aneuploidy of the tumours were obtained from the Department of Pathology, Landspitali University Hospital (Reykjavik, Iceland). This work was carried out according to permits from the Icelandic Data Protection Commission (2004040264; 200403147) and Bioethics Committee (99041V2S1; 99111V1S1).
Methylation specific PCR
DNA methylation of the BRCA1 promoter region was assessed by methylation specific PCR of sodium bisulphite treated DNA . Tumour DNA and controls (1 μg) were treated with sodium bisulphite and purified using the Wizard DNA Clean-Up System (catalogue no. A7280, Promega, Madison, WI) following the manufacturer's recommendations. Modified DNA was amplified with published PCR primers that distinguish unmethylated and methylated DNA. Primer sequences for unmethylated and methylated DNA were as follows: unmethylated forward, ggt taa ttt aga gtt ttg aga gat g; unmethylated reverse, t caa caa act cac acc aca caa tca; methylated forward, ggt taa ttt aga gtt tcg aga gac g; and methylated reverse, tca acg aac tca cgc cgc gca atc g . The primers amplified a 182 base-pair (bp) product corresponding to nucleotides -150 to +32 relative to the main transcription start site of BRCA1. DNA extracted from blood was used as a negative control for methylated BRCA1 alleles. DNA extracted from blood and methylated in vitro was used as a positive control. The PCR solution (15 μl) contained 1 μl of modified DNA in 1X Thermo-Start PCR Master Mix (ABgene, Epsom, UK) and 5 pmol of each primer. The PCR was carried out in a thermocycler with the following conditions: one cycle of 95°C for 15 minutes followed by 35 cycles of 94°C for 30s, 65°C for 30s and 72°C for 60s, ending with one cycle of 72°C for 5 minutes. Then, 6 μl of the PCR product were mixed with 6 μl of 1X loading buffer (98% formamide, 0.1% xylene cyanol, 0.1% bromophenol blue and 10 mM EDTA) and electrophorised on 7.5% polyacrylamide gels.
Allelic imbalance by microsatellite analysis
AI at polymorphic microsatellite markers was analysed by laser quantification of PCR products. We analysed two intragenic BRCA1 markers (D17S855 and D17S1323), located within introns 12 and 20, respectively, and one marker centromeric to the BRCA1 gene (D17S846) located in region 17q12. Two BRCA2 markers were analysed, located in region 13q12, centromeric (D13S260) and telomeric (D13S171) to the gene. The marker primers were of published sequences available from The GDB Human Genome Data Base . The primers were purchased HPLC purified from Eurogentec (Seraing, Belgium) with the forward primers Cy5 indocarbocyanin labelled.
The PCR solution (15 μl) contained 50 ng of DNA, 5 pmol of each primer, 0.2 mM Ultrapure dNTPs (Amersham Pharmacia, Little Chalfont, Buckinghamshire, UK) and 0.36U Dynazyme enzyme mix (Finnzymes, Espoo, Finland) with supplied 1X reaction buffer. A Hot Start was performed by heating the PCR solution in a thermocycler at 94°C for 2 minutes and cooling to 85°C before the enzyme was added to the solution. This was followed by 30 cycles at 94°C for 30s, 64°C to 69°C (annealing temperature varied depending on which primers were used) for 30s and 72°C for 60s, ending with 1 cycle of 72°C for 5 minutes.
The PCR products were mixed in a stop solution (100% deionized formamide and Dextran Blue 2000 (5 mg/ml); Amersham Pharmacia) in ratios varying from 0.13 to 1, denatured at 95°C for 5 minutes and resolved on a 3 mm thick High Resolution Reprogel (Amersham Pharmacia) using an automated laser fluorescent sequencer (ALF Express DNA Sequencer, Amersham Pharmacia). Aliquots of 3 to 5 μl of each sample were loaded onto the gel. The following running parameters were used: 1,500 V, 60 mA, 25 W, 55°C. The sample interval was 2s, the running time 300 minutes and the running buffer 1X TBE (Tris-BoricAcid-EDTA). ALFwin Fragment analyser 1.0 software (Amersham Parmacia) was used to compare the relative quantity of the PCR products. AI was defined if the relative difference of peaks representing alleles in the tumour and the corresponding normal DNA reactions was more than 25%.
Fluorescence in situhybridization
FISH analysis was performed on paraffin embedded and formalin fixed breast tumour tissue sections (sliced in 4 μm sections) using DNA probes for the BRCA1 region and the centromere region of chromosome 17, simultaneously. The probe for the BRCA1 region (PAC103014; the Human BAC Clone Library, Sanger Centre, Hinxton, Cambridge, UK) which spans the entire BRCA1 gene was labelled with SpectrumOrange-dUTP (Vysis, Des Plaines, IL, USA) by nick-translation. Hybridisation efficiency of the BRCA1 probe has previously been tested in non-malignant breast samples . The probe for the centromere region of chromosome 17 (clone D17Z1 in pUC 19: American Type Culture Collection, USA), was used as a copy number reference for BRCA1 and labelled with green fluoroscein-11-dUTP (Amersham Pharmacia) by nick-translation.
Tissue sections were deparaffinized, placed in 0.01 M citric acid solution (pH 6) and heated for 2 × 10 minutes in a microwave oven at maximum power. After cooling, tissue sections were incubated with pepsin at 37°C for 20 minutes followed by dehydration. Probes were diluted in t-DenHyb-2 hybridisation buffer (InSitus Biotechnologies, Albuquerque, NM, USA) as described by the manufacturer. Tissue section chromosomes and probes were simultaneously denatured at 95°C for 10 minutes. This was followed by overnight hybridisation at 37°C in a humid chamber and washing of tissue sections for 3 × 5 min in 0.1X SSC (Saline-Sodium-Citrate) at 60°C and mounting with 4'-6-Diamidino-2-phenylindole (DAPI) counterstaining. Fluorescence signals were scored in each sample by counting the number of single-copy gene and centromeric signals in at least 100 well-defined nuclei. Deletion of BRCA1 was defined if the copy number ratio was 0.8 or less, which has previously been used to detect deletion . Deletion of chromosome 17 was defined if both BRCA1 and centromere mean copy numbers were 1.5 or less.
BRCA1 protein expression analysis was performed on formalin fixed and paraffin embedded malignant breast tissue and adjacent normal tissue (sliced in 4 μm sections), with BRCA1 MS110 antibody (Oncogene Research Products, San Diego, CA, USA). Tissue sections were deparaffinized, placed in 0.01 M citric acid solution (pH 6) and heated for 2 × 10 minutes in a microwave oven at maximum power. The sections were then incubated in 3% H2O2 in order to block endogenous peroxidase activity. The BRCA1 MS110 antibody (100 μg/ml) was used in 1:50 dilution in 1X Tris buffer and incubated in a humid chamber at room temperature overnight. For antibody detection all slides were incubated with StreptABComplex/HRP Duet, Mouse/Rabbit Kit (Code No. K0492: Dako, Glostrup, Denmark) reagents following the manufacturer's recommendations. Counterstaining was performed with haemotoxylin.
Positive staining of normal breast epithelial cells that either co-existed on the tumour sections and/or normal breast tissue sections from the same breast was used as a control. The protein expression levels in tumour sections were measured by eye in three discontinuous classes, as previously described . When the immunoreactivity was comparable to that of the normal breast epithelium or nuclear staining was observed in >50% of tumour cells, it was classified as level 3, that is, wild-type expression. When the staining was clearly weaker than normal surrounding cells or nuclear staining occurred in 20% to 50% of tumour cells, it was classified as level 2, that is, reduced expression. When there was no staining or nuclear staining occurred in <20% of tumour cells, it was classified as level 1, that is, absent/markedly reduced expression.
TP53 mutation analysis was carried out by PCR amplification and constant denaturing gel electrophoresis on exons 5–8. Mutations were confirmed by direct DNA sequencing in an ALF Express DNA Sequencer (Amersham Pharmacia) as previously described .
Proportions were compared by two-tailed Fisher's exact test using GraphPad InStat3 (GraphPad Software Inc., San Diego, CA, USA). Associations with P values of <0.05 were considered to be significant and P values within the range of 0.05 to 0.10 as an indication of an association.
Methylation of the BRCA1promoter
Hypermethylation of the BRCA1α promoter was assayed in 143 primary sporadic breast tumours. Methylation was detected in 9.1% (13/143) of the tumours (Figure 1).
Allelic imbalance at the BRCA1 and BRCA2loci
AI in the BRCA1 region was assessed in all 143 samples (Figure 2a,b). The frequencies of informative cases for polymorphism at the BRCA1 microsatellite marker regions were 72.7% (D17S846), 89.5% (D17S855) and 40.6% (D17S1323). The intragenic markers D17S855 and D17S1323 showed AI in 35.2% and 43.1% of informative cases, respectively (Additional file 1). The exogenic marker D17S846 showed AI in 36.5% of informative cases. AI at the BRCA1 locus was defined if one or both of the intragenic markers (D17S855, D17S1323) displayed AI. According to this definition, 37.4% (49/131) of informative tumours had AI at the BRCA1 locus. Of these 49 tumours, 24 were informative for both intragenic markers, of which all but one displayed AI at both regions (95.8%). Of the cases informative for an intragenic marker and the exogenic marker D17S846 (n = 33), 87.9% displayed AI at both regions.
An indication was found for an association between BRCA1 methylation and AI at the BRCA1 locus (P = 0.0731, odds ratio (OR) = 3.0, 95% confidenece interval (CI) = 0.9–9.8; Table 1). Of the eight BRCA1 methylated tumours that displayed AI at the BRCA1 locus, five were informative for an intragenic marker and the exogenic marker. All these five tumours displayed AI at both regions.
The frequencies of informative cases for polymorphism at the BRCA2 microsatellite marker regions D13S260 and D13S171 were 74.1% and 71.3%, respectively. The D13S260 marker showed AI in 32.1% of informative cases, and the D13S171 marker in 35.3% of informative cases (Additional file 1). AI at the BRCA2 locus was defined if one or both markers displayed AI. According to this definition, 31.1% (42/135) of informative tumours had AI at the BRCA2 locus. Of these 42 tumours, 29 were informative for both markers, of which all but one displayed AI at both regions (96.6%).
AI at the BRCA1 locus was found to be strongly associated with AI at the BRCA2 locus (P < 0.0001, OR = 7.0, 95%CI = 3.0–16.4) with 26 of 124 (21.0%) informative tumours having AI at both loci (Table 1). However, AI at the BRCA2 locus was not found to be associated with BRCA1 methylation (P = 0.5420, OR = 1.4, 95%CI = 0.3–5.3).
FISH analysis at the BRCA1locus
A physical deletion was detected at the BRCA1 locus in six tumours, including four with deletion of chromosome 17 (Table 2). Of these six tumours, all but one (sample 6 in Table 2) showed AI at the BRCA1 locus.
BRCA1 protein expression
BRCA1 protein expression was estimated in all BRCA1 methylated tumours by immunostaining. Nine of the methylated tumours were estimated to have class 1 BRCA1 protein expression, indicating absent or markedly reduced BRCA1 expression (Figure 3b,c; Table 2). Of these nine tumours, all but two had AI at the BRCA1 locus (Table 2). Four tumours were estimated to have class 2 or 3 BRCA1 protein expression (Table 2). Of these four tumours, AI at the BRCA1 locus was detected in one case (Table 2).
Of the 143 primary sporadic breast tumours in this study, 141 were available for TP53 mutation analysis. Mutation was found in 19.1% (27/141) of the tumours. Although not statistically significant, we found the frequency of TP53 mutations to be much higher within the subset of BRCA1 methylated tumours compared with the non-methylated BRCA1 tumours or 38.5% (5/13) compared to 17.2% (22/128), respectively (P = 0.1299, OR = 3.0, 95%CI = 0.9–10.1; Table 1). However, TP53 mutations were only found in those BRCA1 methylated tumours that exhibited absent or markedly reduced BRCA1 expression, in which case the TP53 mutation frequency becomes 55.5% (5 of 9) and the association statistically significant (P = 0.01317, OR = 6.13, 95%CI = 1.21–33.51; Table 2). All the five tumours with BRCA1 methylation and TP53 mutation were found to have AI at the BRCA1 locus (Table 2). Furthermore, all five tumours showed absent or markedly reduced BRCA1 protein expression (Table 2).
Hormonal receptor status and age at diagnosis
Association was found between a negative ER status and BRCA1 methylation (P = 0.0475, OR = 3.4, 95%CI = 1.1–10.9; Table 1). No associations were found between BRCA1 methylation and a negative/positive PR status.
An indication for an association between young age (= 55) at diagnosis and BRCA1 methylation was found (P = 0.0898, OR = 2.9, 95%CI = 0.8–13.4).
Tumour grade and histological type
Of all the 13 BRCA1 methylated tumours, seven were of grade 3, five of grade 2 and one of grade 1. All BRCA1 methylated tumours were of infiltrating ductal type except for one that was of a lobular type.
We report here that hypermethylation of the BRCA1 gene promoter is found in a considerable proportion of primary sporadic breast carcinomas, that is, 13 of 143 (9.1%), which is in the lower end of previously reported frequencies for this alteration in sporadic breast tumours [14, 33, 34].
Absent or markedly reduced BRCA1 protein expression was evident in the majority of the BRCA1 methylated tumours (9 of 13), suggesting transcriptional silencing in these tumours by epigenetic modifications. A trend for AI at the BRCA1 locus was observed in the subset of BRCA1 methylated tumours (P = 0.0731). All the BRCA1 methylated tumours that had AI at the BRCA1 locus and were informative for AI at the exogenic and an intragenic marker displayed AI at both regions, indicating a rather large deletion at chromosome 17. This is supported by the FISH analysis, which revealed deletion of chromosome 17 in most of the BRCA1 methylated tumours that had a detectable BRCA1 deletion. Importantly, the FISH analysis revealed substantial heterogeneity in BRCA1 gene copy numbers between individual cells in the BRCA1 methylated tumours, demonstrating that AI as detected by polymorphic microsatellite PCR analysis does not infer a simple loss of one BRCA1 allele but, rather, it appears to reflect complex genetic rearrangements.
AI at the BRCA1 and BRCA2 loci are know to be relatively common in breast tumours . The implications of AI at the BRCA1 and/or BRCA2 loci for sporadic breast tumorigenesis remain unknown since Knudson's hypothesis predicts that two 'hits' are required for tumorigenesis to occur . Our results confirm that AI at the BRCA1 and BRCA2 loci are common events in sporadic breast tumours, present in 37.4% (49/131) and 31.1% (42/135) of primary sporadic breast tumours, respectively. A significant association was found between AI at the BRCA1 and BRCA2 loci (P < 0.0001). Importantly, we found an indication for AI at the BRCA1 locus to be associated with BRCA1 methylation (P = 0.0731) whereas AI at the BRCA2 locus was not found to be associated with BRCA1 methylation (P = 0.5420). This has not been shown previously and suggests that AI at the BRCA1 locus is specifically associated with BRCA1 methylation. Thus, copy number alterations and epigenetic silencing of the BRCA1 gene in sporadic breast cancer could serve as Knudson's 'hits', which has previously been proposed by Esteller and colleagues . Indeed, all but one of the BRCA1 methylated tumours that had absent/markedly reduced BRCA1 protein expression (8 of 9) also had a detectable deletion of the BRCA1 gene. Collectively, these results suggest that the BRCA1 gene is implicated in sporadic breast tumorigenesis through epigenetic silencing and deletion of the BRCA1 gene. Indications that BRCA1 methylation is important in hereditary breast cancer have been reported .
The failure to detect a BRCA1 deletion in one of the tumours that exhibited absent or markedly reduced BRCA1 expression could mean that promoter hypermethylation is present on both alleles, thereby alleviating any selection pressure for deletion at the BRCA1 locus. Alternatively, the level of detection in the FISH analysis could be limited by the small proportion of tumour cells present in each tumour section analysed. This might also apply for those tumours in which AI was present without a detectable deletion by FISH. Conversely, the detection level of the AI analysis was limited by the fact that none of the tumours were micro/macrodissected prior to DNA isolation, which also means that unmethylated BRCA1 alelles are always detected in the tumour samples due to the presence of normal DNA.
The four BRCA1 methylated tumours that did not exhibit significantly reduced BRCA1 expression could possibly be heterogenous with respect to this alteration. None of the four tumours exhibited BRCA1 deletion by FISH and only one displayed AI at the BRCA1 locus. Alternatively, DNA methylation might not bring about transcriptional silencing in all instances.
Although the etiology of cancer predisposition in individuals carrying a germline BRCA1 mutation is not clear, increased genomic instability in BRCA1 deficient cells is undoubtedly of importance since it is predicted to result in increased probability of further genetic alterations and gene mutations, which might result in functional consequences by which tumorigenic potential could be acquired. Genomic instability, however, is a potent inducer of apoptosis where cell survival is dependent upon dysfunctional checkpoint mechanisms . Indeed, familial BRCA1 tumours are associated with mutations in the TP53 checkpoint gene, supporting the notion that genomic instability is an important driving force in early-onset familial BRCA1 tumorigenesis . Association of BRCA1 methylation with TP53 mutations has not been shown previously. Our results show a higher frequency of TP53 mutations among the BRCA1 methylated tumours compared with the non-methylated tumours or 38.5% (5 of 13) and 17.2% (22 of 128), respectively (P = 0.1299, OR = 3.0, 95%CI = 0.9–10.1). This association was not statistically significant, although the TP53 mutations were found to be entirely limited to those BRCA1 methylated tumours that exhibited absent or markedly reduced BRCA1 expression, in which case the frequency of TP53 mutations becomes 55.5% (5 of 9) and the association statistically significant (P = 0.01317, OR = 6.13, 95%CI = 1.21–33.51). Reinforcing this idea is the observation that all the five BRCA1 methylated tumours with a TP53 mutation had a detectable BRCA1 copy number reduction and the majority of these tumours had a relatively high DNA index, suggesting genomic instability (Table 2).
It has previously been suggested that BRCA1 methylated tumours might phenocopy familial BRCA1 tumours . In support of this notion, we observed ER negativity to be significantly associated with BRCA1 methylation (P = 0.0475), a well established characteristic of familial BRCA1 tumours previously reported by Catteau and colleagues  and others. However, Matros and colleagues , looking at gene expression profiles, found a high frequency of BRCA1 promoter methylation among high-grade ER positive tumours, suggesting a more complex phenotype association. We found an indication for BRCA1 methylation to be specifically associated with AI at the BRCA1 locus and an elevated frequency of TP53 mutations, which has not been reported previously. In addition, we found a considerable proportion of the BRCA1 methylated tumours (7 of 13) to be of grade 3, with only one tumour of grade 1, as well as an indication of an association between BRCA1 methylation and an early age of onset (P = 0.0898) as previously reported by Wei and colleagues .
It has been suggested that breast cancers arising in individuals carrying a germline mutation in the BRCA genes could benefit from therapeutic agents that lead to DNA cross-links or double-strand breaks at replication forks, for example, mitomycin C, cisplatin, diepoxybutane and, more recently, poly(ADP-ribose) polymerase (PARP) inhibitors . These therapeutic agents could also be effective for sporadic breast cancers with abnormalities in the BRCA genes, which is, as shown here, a considerably larger proportion of all breast cancer patients than germline BRCA1 or BRCA2 mutation carriers. In addition, abnormalities in other genes regulating homologous recombination could also be of relevance. This emphasizes the importance of developing methods for identifying BRCA-like cancers, regardless of the underlying alterations .
Our results show promoter hypermethylation of the BRCA1 gene in a considerable proportion of all primary sporadic breast tumours. The majority of the BRCA1 methylated tumours were found to have absent or markedly reduced BRCA1 expression, suggesting transcriptional silencing by epigenetic modifications. In addition, we found an indication for AI at the BRCA1 locus to be associated with BRCA1 methylation whereas AI at the BRCA2 locus was not associated with BRCA1 methylation. This indicates that AI at the BRCA1 locus is specifically associated with BRCA1 methylation. The genetic alterations at the BRCA1 locus were further examined by FISH, which revealed chromosome 17 deletions and heterogeneity with respect to chromosomal abnormalities. These results imply that methylation of the BRCA1 gene is accompanied by genomic rearrangements at the BRCA1 locus, resulting in loss of genetic material containing non-methylated BRCA1 alleles and retention of methylated BRCA1 alleles. We also found a substantially elevated frequency of TP53 mutations in the subset of BRCA1 methylated tumours, which has not been reported previously, suggesting that BRCA1 methylation might lead to alterations in the same molecular pathways as those known to be commonly altered in familial BRCA1 tumours. Collectively, these results implicate epigenetic silencing of the BRCA1 gene in sporadic breast tumorigenesis.
Medullary histological type was not found in the BRCA1 methylated tumours. However, we observed ER negativity to be significantly associated with BRCA1 methylation. We also found a substantial proportion of the BRCA1 methylated tumours to be of grade 3 and an indication for an association between BRCA1 methylation and early age of onset. Thus, our results indicate phenotypic similarities between BRCA1 methylated and familial BRCA1 breast tumours.
fluorescence in situ hybridisation
Arver B, Du Q, Chen J, Luo L, Lindblom A: Hereditary breast cancer: a review. Semin Cancer Biol. 2000, 10: 271-288. 10.1006/scbi.2000.0325.
Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF, et al: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13. Oncogene. 1995, 10: 1673-1675.
Smith SA, Easton DF, Evans DG, Ponder BA: Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 1992, 2: 128-131. 10.1038/ng1092-128.
Scully R, Livingston DM: In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000, 408: 429-432. 10.1038/35044000.
Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD: TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 2001, 61: 4092-4097.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994, 266: 120-122.
Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, et al: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996, 13: 238-240. 10.1038/ng0696-238.
Johnson SM, Shaw JA, Walker RA: Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer. 2002, 98: 205-209. 10.1002/ijc.10197.
Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971, 68: 820-823. 10.1073/pnas.68.4.820.
Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038/nrg962.
Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61: 3225-3229.
Feinberg AP: The epigenetics of cancer etiology. Semin Cancer Biol. 2004, 14: 427-432. 10.1016/j.semcancer.2004.06.005.
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92: 564-569. 10.1093/jnci/92.7.564.
Collins N, Wooster R, Stratton MR: Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer. 1997, 76: 1150-1156.
Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002, 94: 1396-1406.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001, 344: 539-548. 10.1056/NEJM200102223440801.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.
Honrado E, Benitez J, Palacios J: The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005, 18: 1305-1320. 10.1038/modpathol.3800453.
Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer . 1998, 83: 310-319. 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W.
Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996, 56: 471-474.
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.
Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, Honrado E, Rodriguez R, Urioste M, Valle L, et al: A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 2005, 11: 1146-1153.
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL: BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005, 91: 179-186. 10.1007/s10549-004-7603-8.
Bergthorsson JT, Jonasdottir A, Johannesdottir G, Arason A, Egilsson V, Gayther S, Borg A, Hakanson S, Ingvarsson S, Barkardottir RB: Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat. 1998, S195-197.
Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-119. 10.1038/ng0596-117.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821.
Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY: BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000, 60: 5329-5333.
GDB Human Genome Data Base. [http://www.gdb.org]
Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM: Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer. 2000, 28: 432-442. 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J.
Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, et al: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999, 21: 236-240. 10.1038/6029.
Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, Jonasson JG, Ogmundsdottir H, Eyfjord JE: P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol. 2000, 22: 268-274. 10.1002/(SICI)1097-0339(200005)22:5<268::AID-DC2>3.0.CO;2-X.
Staff S, Isola J, Tanner M: Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003, 63: 4978-4983.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, et al: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65: 10692-10699. 10.1158/0008-5472.CAN-05-1277.
Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, et al: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001, 10: 3001-3007. 10.1093/hmg/10.26.3001.
Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004, 4: 814-819. 10.1038/nrc1457.
Catteau A, Harris WH, Xu CF, Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999, 18: 1957-1965. 10.1038/sj.onc.1202509.
Turner N, Tutt A, Ashworth A: Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005, 5: 388-393. 10.1016/j.coph.2005.03.006.
We thank the Department of Pathology and The Icelandic University Hospital for their collaboration, the Icelandic Cancer Society Biobank for supplying samples, Professor Magnus Johannsson for statistical advise and Gudridur Olafsdottir for data management. This work was supported by The University of Iceland Research Fund, Icelandic Research Foundation Graduate Student Grants (VB, OAS, SKB). The memorial fund of Bergthora Magnusdottir and Jakob Bjarnason (SKB), and The Icelandic Cancer Society.
The authors declare that they have no competing interests.
VB and OAS contributed equally to this work, performing a substantial part of the analysis, participation in design and contribution to the writing of the manuscript. SKB contributed to FISH analysis, HH to TP53 analysis and JGJ to supervision and analysis of pathological data and immunostaining. JEE conceived of the study, was in charge of its design and coordination and the writing of the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1: An Excel file containing results of the FISH analysis along with DNA index and proportion of aneuploid cells. (XLS 19 KB)
About this article
Cite this article
Birgisdottir, V., Stefansson, O.A., Bodvarsdottir, S.K. et al. Epigenetic silencing and deletion of the BRCA1gene in sporadic breast cancer. Breast Cancer Res 8, R38 (2006). https://doi.org/10.1186/bcr1522
- TP53 Mutation
- BRCA1 Gene
- Allelic Imbalance
- Sporadic Breast Cancer
- BRCA1 Promoter